Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2024Autophagy ReportsOpen Access

Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EBElisabetta BartoliniKMKris Van MoerBJBassam Janji

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bartolini et al. (2024) studied this question.

synapsesocial.com/papers/68e5fee2b6db643587592461https://doi.org/10.1080/27694127.2024.2370728
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combining <scp>VPS34</scp> inhibitors with <scp>STING</scp> agonists enhances type I interferon signaling and anti‐tumor efficacy2024 · 7 citations
  2. 2Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS342024 · 1 citations
  3. 3Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth2026 · 1 citations
  4. 4Targeting VCP enhances colorectal cancer therapy through STING stabilization2025
  5. 5VPS34-IN1 inhibits cap-mediated translation and synergizes with STING to drive type-I IFN expression in human plasmacytoid DCs2024 · 1 citations